Researchers of the firm have demonstrated the hLEC cells engraftment and bioactivity in vivo and their expandable capability.
The newly issued ‘164 patent, which extends to 2022, has relevance to the deriving liver cells from iPS or ESC platforms.
StemCells president and chief executive officer Martin McGlynn said the development benefits those looking for an expandable human liver cell.
"Because the liver is such a key organ, finding an expandable, reliable and well-characterized liver cell population is an important step forward in both medical research and drug development,” McGlynn added.
In October 2011, StemCells formed a wholly-owned subsidiary to focus on therapeutic and research tool applications of its hLEC technologies and to serve as an investment vehicle for those interested in a liver cell company.